Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Chris Lange | Jan 22, 2018 at 12:35 PM EST

Nymox Pharmaceutical Screams Higher on Prostate Cancer Study

Nymox Pharmaceutical watched its shares make a solid gain on Monday after the firm announced five-year results from its prostate…

Chris Lange | Jan 22, 2018 at 10:25 AM EST

Sanofi Moves to Acquire Bioverativ

Bioverativ is adding to Monday’s M&A news after it was announced that Sanofi would be acquiring the firm.

Chris Lange | Jan 22, 2018 at 10:10 AM EST

Why Celgene Is Betting Big on 2020 With Juno Acquisition

Juno Therapeutics saw its shares take off early on Monday after it was announced that Celgene would be acquiring it.

Chris Lange | Jan 19, 2018 at 10:25 AM EST

Menlo Therapeutics Closes in on IPO

Menlo Therapeutics plans on pricing its more than 5 million shares in a range that results in an initial public…

Jon C. Ogg | Jan 18, 2018 at 11:40 AM EST

Credit Suisse Outlines Top Biotech M&A Targets and Catalyst Stocks for 2018

Credit Suisse sees tax reform sparking a wave of mergers in the emerging pharmaceuticals space, which could produce sector outperformance.…

Chris Lange | Jan 18, 2018 at 10:45 AM EST

Investors Cheer BeiGene’s Secondary Offering

BeiGene saw its shares make a handy gain on Thursday after the company announced that it would be conducting a…

Chris Lange | Jan 17, 2018 at 11:35 AM EST

Exelixis Slides Despite Positive Late-Stage Results

Shares of Exelixis slipped on Wednesday after the company reported results from its late-stage trial of cabozantinib for advanced hepatocellular…

Chris Lange | Jan 17, 2018 at 10:45 AM EST

ARMO Announces Potential Pricing for IPO

ARMO BioSciences intends to price more than 6. million shares in a range that results in an initial public offering…

Chris Lange | Jan 17, 2018 at 10:15 AM EST

Why Juno Therapeutics Is Soaring

Juno Therapeutics saw its shares skyrocket early on Wednesday after reports that Celgene was in talks to acquire the company.

Jon C. Ogg | Jan 16, 2018 at 3:01 PM EST

Canaccord Genuity Issues Top 5 Diagnostics Picks for 2018

Canaccord Genuity's diagnostics analyst Mark Massaro has released his own top picks for 2018. These top five picks in the space have…

Chris Lange | Jan 16, 2018 at 10:45 AM EST

Why Eiger BioPharma Shares Are Getting Crushed

Eiger BioPharmaceuticals watched its shares crater on Tuesday after the firm announced that its midstage study in pulmonary arterial hypertension…

Chris Lange | Jan 16, 2018 at 9:58 AM EST

Merck Wins Big With Late-Stage Lung Cancer Drug Results

Merck saw its shares make a handy gain on Tuesday after it reported that a late-stage trial of Keytruda met…

Paul Ausick | Jan 16, 2018 at 7:40 AM EST

How the New Tax Law Boosted UnitedHealth Earnings and Forecast

UnitedHealth reported fourth-quarter and full-year results Tuesday morning that beat analysts estimates. The company also raised guidance for 2018 based…

Paul Ausick | Jan 15, 2018 at 11:30 AM EST

What to Expect From UnitedHealth Group Earnings

UnitedHealth Group reports fourth-quarter and full-year 2017 earnings Tuesday morning before the markets open. Analysts are expecting another solid performance…

Chris Lange | Jan 13, 2018 at 8:55 AM EST

Meet the Top Biotech Movers of This Past Week

Over the past week, a few biotech companies made absolutely massive runs, while others fell off a cliff. Here are…

1 … 144 145 146 147 148 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Nymox Pharmaceutical Screams Higher on Prostate Cancer Study

Sanofi Moves to Acquire Bioverativ

Why Celgene Is Betting Big on 2020 With Juno Acquisition

Menlo Therapeutics Closes in on IPO

Credit Suisse Outlines Top Biotech M&A Targets and Catalyst Stocks for 2018

Investors Cheer BeiGene’s Secondary Offering

Exelixis Slides Despite Positive Late-Stage Results

ARMO Announces Potential Pricing for IPO

Why Juno Therapeutics Is Soaring

Canaccord Genuity Issues Top 5 Diagnostics Picks for 2018

Why Eiger BioPharma Shares Are Getting Crushed

Merck Wins Big With Late-Stage Lung Cancer Drug Results

How the New Tax Law Boosted UnitedHealth Earnings and Forecast

What to Expect From UnitedHealth Group Earnings

Meet the Top Biotech Movers of This Past Week

The Reverse Mortgage Line of Credit That Grows Untouched for 15 Years and Becomes a $700,000 Liquidity Buffer at 80

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how

The Reverse Mortgage Line of Credit That Grows Untouched for 15 Years and Becomes a $700,000 Liquidity Buffer at 80

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Health and Healthcare Articles

All Health and Healthcare Articles

Nymox Pharmaceutical Screams Higher on Prostate Cancer Study

Sanofi Moves to Acquire Bioverativ

Why Celgene Is Betting Big on 2020 With Juno Acquisition

Menlo Therapeutics Closes in on IPO

Credit Suisse Outlines Top Biotech M&A Targets and Catalyst Stocks for 2018

Investors Cheer BeiGene’s Secondary Offering

Exelixis Slides Despite Positive Late-Stage Results

ARMO Announces Potential Pricing for IPO

Why Juno Therapeutics Is Soaring

Canaccord Genuity Issues Top 5 Diagnostics Picks for 2018

Why Eiger BioPharma Shares Are Getting Crushed

Merck Wins Big With Late-Stage Lung Cancer Drug Results

How the New Tax Law Boosted UnitedHealth Earnings and Forecast

What to Expect From UnitedHealth Group Earnings

Meet the Top Biotech Movers of This Past Week

The Reverse Mortgage Line of Credit That Grows Untouched for 15 Years and Becomes a $700,000 Liquidity Buffer at 80

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Featured Reads

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how